Trial Profile
A Phase II Trial of sEphB4-HSA in Combination With Anti PD1 Antibody Pembrolizumab (MK-3475) for Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; SEphB4-HSA (Primary)
- Indications Bladder cancer; Carcinoma; Prostate cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- 14 Feb 2024 Planned End Date changed from 21 Nov 2024 to 21 Nov 2025.
- 14 Feb 2024 Planned primary completion date changed from 21 Nov 2023 to 21 Nov 2025.
- 19 Aug 2022 Results (n=70) assessing EphrinB2 inhibition and pembrolizumab in metastatic urothelial carcinoma published in the journal of clinical oncology